JP2011518886A5 - - Google Patents

Download PDF

Info

Publication number
JP2011518886A5
JP2011518886A5 JP2011507586A JP2011507586A JP2011518886A5 JP 2011518886 A5 JP2011518886 A5 JP 2011518886A5 JP 2011507586 A JP2011507586 A JP 2011507586A JP 2011507586 A JP2011507586 A JP 2011507586A JP 2011518886 A5 JP2011518886 A5 JP 2011518886A5
Authority
JP
Japan
Prior art keywords
region
antibody
seq
sequence
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011507586A
Other languages
English (en)
Japanese (ja)
Other versions
JP5688363B2 (ja
JP2011518886A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/041981 external-priority patent/WO2009134805A2/en
Publication of JP2011518886A publication Critical patent/JP2011518886A/ja
Publication of JP2011518886A5 publication Critical patent/JP2011518886A5/ja
Application granted granted Critical
Publication of JP5688363B2 publication Critical patent/JP5688363B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011507586A 2008-04-28 2009-04-28 顆粒球−マクロファージコロニー刺激因子に対する抗体 Active JP5688363B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4852208P 2008-04-28 2008-04-28
US61/048,522 2008-04-28
PCT/US2009/041981 WO2009134805A2 (en) 2008-04-28 2009-04-28 Antibodies to granulocyte-macrophage colony-stimulating factor

Publications (3)

Publication Number Publication Date
JP2011518886A JP2011518886A (ja) 2011-06-30
JP2011518886A5 true JP2011518886A5 (enExample) 2012-06-21
JP5688363B2 JP5688363B2 (ja) 2015-03-25

Family

ID=41255734

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011507586A Active JP5688363B2 (ja) 2008-04-28 2009-04-28 顆粒球−マクロファージコロニー刺激因子に対する抗体

Country Status (17)

Country Link
US (3) US8168183B2 (enExample)
EP (2) EP2280732B1 (enExample)
JP (1) JP5688363B2 (enExample)
KR (2) KR101852915B1 (enExample)
CN (1) CN102037016B (enExample)
AU (1) AU2009243184B2 (enExample)
BR (1) BRPI0911902A2 (enExample)
CA (1) CA2722137C (enExample)
CO (1) CO6311004A2 (enExample)
DK (1) DK2280732T3 (enExample)
EA (1) EA201001691A1 (enExample)
ES (1) ES2704835T3 (enExample)
IL (1) IL208980A (enExample)
MX (1) MX2010011761A (enExample)
NZ (1) NZ588850A (enExample)
WO (1) WO2009134805A2 (enExample)
ZA (1) ZA201008028B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2661848C (en) 2006-09-01 2015-02-03 Therapeutic Human Polyclonals, Inc. Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
EA201001691A1 (ru) 2008-04-28 2011-10-31 Калобайос Фармасьютикалз, Инк. Антитела к гранулоцитарно-макрофагальному колониестимулирующему фактору
AU2009329814B2 (en) 2008-12-22 2015-06-18 The University Of Melbourne Osteoarthritis treatment
WO2010071923A1 (en) 2008-12-22 2010-07-01 The University Of Melbourne Pain treatment
US8512950B2 (en) 2010-07-21 2013-08-20 Saint Louis University Biolayer interferometry measurement of biological targets
RU2013156435A (ru) 2011-07-06 2015-08-20 МорфоСис АГ Терапевтические комбинации анти-cd20 и анти-gm-csf антител и их применения
US9400600B2 (en) * 2011-12-16 2016-07-26 Samsung Electronics Co., Ltd. Method, apparatus, and graphical user interface for providing visual effects on a touchscreen display
WO2013090989A1 (en) 2011-12-22 2013-06-27 Csl Limited Method of treating inflammatory bowel disease
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
JP6339578B2 (ja) 2012-10-31 2018-06-06 タケダ・ゲー・エム・ベー・ハーTakeda GmbH Gm−csf中和化合物を含む凍結乾燥製剤
CN105705518A (zh) * 2013-08-30 2016-06-22 塔科达有限责任公司 用于治疗类风湿性关节炎或作为镇痛药的中和gm-csf的抗体
EP3139960B1 (en) 2014-05-07 2024-01-17 Takeda Pharmaceutical Company Limited Liquid formulation comprising gm-csf neutralizing compound
CN113862300A (zh) * 2015-10-29 2021-12-31 豪夫迈·罗氏有限公司 具有共同轻链的转基因兔
US11130805B2 (en) 2017-10-02 2021-09-28 Humanigen, Inc. Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
US10870703B2 (en) * 2017-10-02 2020-12-22 Humanigen, Inc. Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist
JP2022517461A (ja) * 2018-09-10 2022-03-09 ヒューマニゲン インコーポレイティッド Gm-csfアンタゴニストを使用した免疫療法関連毒性の治療方法
US20220040229A1 (en) 2018-10-31 2022-02-10 Humanigen, Inc. Materials and methods for treating cancer
US20220395532A1 (en) 2019-11-08 2022-12-15 Humanigen, Inc. Epha3 directed car-t cells for treatment of tumors
CN118561999B (zh) * 2024-06-26 2025-03-14 武汉爱博泰克生物科技有限公司 抗人粒细胞-巨噬细胞集落刺激因子抗体、抗体对及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US7381801B2 (en) 2002-02-13 2008-06-03 Ludwig Institute For Cancer Research Chimerized GM-CSF antibodies
AU2003244817B2 (en) * 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
AU2004205684A1 (en) * 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
AU2005207003C1 (en) 2004-01-20 2013-06-13 Humanigen, Inc. Antibody specificity transfer using minimal essential binding determinants
AU2005306502B2 (en) * 2004-11-16 2012-11-15 Humanigen, Inc. Immunoglobulin variable region cassette exchange
US7381802B2 (en) * 2005-04-15 2008-06-03 Universidad Nacional Autónoma De México (UNAM) Human antibodies that specifically recognize the toxin Cn2 from Centruroides noxius scorpion venom
UA94403C2 (ru) * 2005-04-18 2011-05-10 Микромет Аг Человеческое моноклональное антитело, которое нейтрализует gm-csf
SI3620171T1 (sl) * 2005-05-18 2022-09-30 Morphosys Ag Protitelesa proti GM-CSF in uporabe zanje
US8211648B2 (en) 2005-07-22 2012-07-03 Kalobios Pharmaceuticals, Inc. Secretion of antibodies without signal peptides from bacteria
KR20080068004A (ko) * 2005-08-15 2008-07-22 아라나 테라퓨틱스 리미티드 뉴 월드 영장류 구조형성영역을 가진 조작 항체
WO2007092939A2 (en) * 2006-02-08 2007-08-16 Morphotek, Inc. Antigenic gm-csf peptides and antibodies to gm-csf
US8398972B2 (en) * 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
EP2402013A1 (en) * 2006-11-21 2012-01-04 Kalobios Pharmaceuticals, Inc. Methods of Treating Chronic Inflammatory Diseases using a GM-CSF Antagonist
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
US8075885B2 (en) * 2008-04-07 2011-12-13 Kalobios Pharmaceuticals, Inc. Methods of treating heart failure using an anti-GM-CSF antibody
EA201001691A1 (ru) 2008-04-28 2011-10-31 Калобайос Фармасьютикалз, Инк. Антитела к гранулоцитарно-макрофагальному колониестимулирующему фактору

Similar Documents

Publication Publication Date Title
JP2011518886A5 (enExample)
JP2009511480A5 (enExample)
JP2008542278A5 (enExample)
JP2010526028A5 (enExample)
JP2023061927A5 (enExample)
JP2022061992A5 (enExample)
JP2012504955A5 (enExample)
JP2013502204A5 (enExample)
JP2014511179A5 (enExample)
JP2008515446A5 (enExample)
JP2007097598A5 (enExample)
JP2009225799A5 (enExample)
JP2016524463A5 (enExample)
JP2011504501A5 (enExample)
JP2012501670A5 (enExample)
EP3374392A1 (en) Improved serum albumin-binding immunoglobulin variable domains
JP2009511579A5 (enExample)
JP2011514150A5 (enExample)
JP2019031567A5 (enExample)
JP2006512899A5 (enExample)
JP2013508292A5 (enExample)
JP2009517057A5 (enExample)
JP2017501711A5 (enExample)
JP2011528902A5 (enExample)
JP2011518125A5 (enExample)